You are viewing a preview of...

Targeted Antibody Therapeutics

Highly potent SARS-CoV-2 antibodies show preclinical efficacy and delayed disease progression

Background

The COVID-19 pandemic has emphasized the need for the global community to rapidly acquire a diverse arsenal of prevention and therapeutic options to address SARS-CoV-2. A flexible and robust solution is needed to impact the current threat and shorten the lead time for discovery of therapeutics for future outbreaks. To address this critical need and support our nation’s commitment to the health of the global community, Sandia National Laboratories has developed an antibody discovery platform for mitigating current and future biological threats.

Log in or create a free account to continue reading